Content about Maryland

SILVER SPRING, Md. Patients taking a certain class of drugs mostly used for prostate cancer may be at higher risk of heart disease and diabetes, the Food and Drug Administration warned on Wednesday.

EDGEWOOD, Md. CosaminASU was named a preferred joint health supplement in a new book, "FrameWork for the Knee."

“In 'FrameWork for the Knee,' Dr. Nick DiNubile continues to stress the importance of exercise, nutrition and the mind in maintaining health,” said Troy Henderson, VP corporate operations and professional services at Nutramax Labs. “Physicians repeatedly recommended Cosamin products because of their high-quality ingredients and Nutramax Labs's strict adherence to [good manufacturing practices].”

BETHESDA, Md. The American Podiatric Medical Association recently issued a series of recommendations for runners, including the use of a self-massager designed for post-athletic activities. Specifically, the association recommended Health Enterprises’ therapeutic hot-and-cold foot massager, a product that carries the APMA seal of approval.

SILVER SPRING, Md. Clinical trial data indicating an increased risk of heart attack and stroke has led to the removal from the market of an obesity drug made by Abbott, the Food and Drug Administration said Friday.

The FDA said the drug maker voluntarily withdrew the drug Meridia (sibutramine) following a required post-marketing trial showing that the drug increased by 16% the risk of nonfatal heart attacks and strokes, the need for resuscitation after the heart stopped and death.

BETHESDA, Md. Relatively healthy patients with Type 2 diabetes experienced a significant reduction in blood-sugar levels when taking an investigational treatment for Type 2 diabetes made by Spherix, the biotechnology company said Thursday.

Spherix announced results of a phase-3 trial of D-tagatose, which showed that the drug was more effective in American patients than in Indian patients.

ROCKVILLE, Md. Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment for hepatitis C following the Food and Drug Administration’s decision to decline its approval, HGS said Tuesday.

HGS said it received a complete response letter from the FDA concerning the drug Zalbin (albinterferon alfa-2b). The FDA delivers a complete response letter to indicate that it has finished reviewing an application, but questions remain that preclude final approval.

SILVER SPRING, Md. The Food and Drug Administration on Tuesday issued warning letters to three companies that manufacture and market mouth rinse products with claims that they remove plaque above the gum line or promote healthy gums. According to the FDA, these claims suggested the products are effective in preventing gum disease when no such benefit has been demonstrated.

Warning letters were sent to: Johnson & Johnson (Listerine total care anti-cavity mouthwash), CVS (CVS complete care anti-cavity mouthwash), and Walgreens (Walgreen mouth rinse full action).